Fresenius (FRE) Q4 2023 earnings summary

Executive summary

• FY 2023 revenue was €22,299m, up 6% organically; EBIT before special items was €2,262m, up 2% in constant currency.

• Q4 revenue was €5,678m, with 5% organic growth; EBIT before special items rose 8% in constant currency to €634m.

• FY operating cash flow rose 5% to €2,131m; 2024 priorities include earnings growth, cost savings, debt reduction, capital efficiency and innovation.

• 2024 guidance targets 3%–6% organic revenue growth and 4%–8% constant-currency EBIT growth; the 2025 savings target is ~€400m.

Financial highlights

• FY revenue was €22,299m versus €21,532m in 2022, up 4% reported and 6% organically and in constant currency.

• FY EBIT before special items was €2,262m, up 2% in constant currency; margin was 10.1% versus 10.2% in 2022.

• FY net income before special items fell 13% to €1,505m; reported net loss was €594m, mainly reflecting non-cash IFRS 5 valuation effects.

• Q4 net income excluding FMC was €314m, down 22%; interest expense was €118m versus €80m in Q4 2022.

• FY cost savings reached €282m, exceeding the ~€200m target; €221m was achieved in 2023 against one-time costs.

Outlook and guidance

• FY 2024 organic revenue growth is expected at 3%–6%; EBIT growth before special items is expected at 4%–8% in constant currency, based on adjusted FY 2023 revenue of €21,776m and EBIT of €2,220m.

• Kabi expects mid-single-digit organic revenue growth and ~15% EBIT margin; Helios expects low- to mid-single-digit growth and a 9%–11% margin.

• Vamed expects mid-single-digit organic growth in continuing business; its EBIT margin is expected 1–2 percentage points below the 4%–6% structural band, with return to the band targeted by 2025.

• FY 2024 cost savings are expected at €330–350m, including incremental savings of €50–70m; the FY 2025 target rose to ~€400m.

• FY 2024 expectations include interest expense of €420–440m, tax rate of 25%–26%, capex ~5% of revenue, ROIC of 5.4%–6.0% and leverage of 3.0x–3.5x net debt/EBITDA.